RealDeals Private Equity Awards 2019: Private Equity team shortlisted for Regional Adviser of the Year
The Private Equity team are delighted to have been shortlisted for the fourth year running for the Regional/ Specialist Legal Adviser of the Year Advisory Award at the 2019 Real Deals Private Equity Awards.
Now in their eighteenth year, these awards are the oldest, most respected accolades bestowed on the private equity industry and those that advise it. This award recognises the overall achievement of regional legal advisers in the calendar year of 2018, reflecting success in creating value for clients through outstanding execution, commercial awareness and ability to deliver creative solutions to problems, as well as the overall evolution of team and strategy.
Malcolm MacDougall, Head of Private Equity at Charles Russell Speechlys said: “It’s great to be shortlisted again for this award. Our submission this year reflected our capacity as a team to provide commercially innovative advice, managing teams over various jurisdictions, and offering a long-standing client with a well-rounded, comprehensive service”.
Clients FPE Capital and Bestport Ventures have also been shortlisted (for UK Small Deal of the Year) for their successful sale of Creditcall to US trade buyer NMI, which is backed by Francisco Partners and Great Hill Partners. Charles Russell Speechlys advised both FPE Capital and Bestport Ventures on the deal.
The winners will be announced at the Awards ceremony dinner at the London Hilton on Park Lane in April.
News & Insights
Charles Russell Speechlys advises AgDevCo on investment into Rwandan maize producer and on Ugandan joint venture
AgDevCo is a social impact investor and project developer operating exclusively in the agriculture sector in Sub-Saharan Africa.
Transparency as a rule
It is time to register in the Luxembourg Register of Effective Beneficiaries.
Charles Russell Speechlys advises Apposite Capital on their investment into Mirada Medical
Mirada is a leading AI software developer for streamlining cancer treatment planning applications.